Try

Arcutis Biotherapeutics, Inc.

ARQTUnited States

37 filed reports · 367 financial concepts · 2 earnings calls

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

FigureLatest fiscal yearLatest quarter
Revenue$376MFY2025 · to Dec 31, 2025+91.3% from $197M10-K$144MQ3 FY2026 · to Sep 30, 2026+45.1% from $99.2M10-Q
Net income-$16.1MFY2025 · to Dec 31, 2025a year earlier: -$140M10-K$8.8MQ3 FY2026 · to Sep 30, 2026+18.8% from $7.41M10-Q
Operating income-$12.2MFY2025 · to Dec 31, 2025a year earlier: -$128M10-K$9.44MQ3 FY2026 · to Sep 30, 2026+10.7% from $8.53M10-Q

Filed reports

37 reports · Mar 2020 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 10 guidance figures, 52 earnings-release figures, 10 commentary passages.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR213,370Mar 2020 to Sep 2026
Annual · 10-KSEC EDGAR62,700Dec 2020 to Dec 2025
Current · 8-KSEC EDGAR564Dec 2024 to Sep 2026
Quarterly · 10-Q/ASEC EDGAR33Mar 2023 to Mar 2024
Annual · 10-K/ASEC EDGAR22Dec 2021 to Dec 2022

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q38-KSep 30, 2026Nov 4, 202654Open
FY2026 Q310-QSep 30, 2026Nov 4, 2026374Open
FY2026 Q210-QJun 30, 2026Aug 5, 2026221Open
FY2026 Q28-KJun 30, 2026Aug 5, 20262Open
FY2026 Q110-QMar 31, 2026May 6, 2026213Open
FY2025 Q48-KDec 31, 2025Feb 25, 20262Open
FY202510-KDec 31, 2025Feb 25, 2026818Open
FY2025 Q310-QSep 30, 2025Oct 28, 2025178Open
FY2025 Q38-KSep 30, 2025Oct 28, 20252Open
FY2025 Q210-QJun 30, 2025Aug 6, 2025139Open
FY2025 Q110-QMar 31, 2025May 6, 2025156Open
FY202410-KDec 31, 2024Feb 25, 2025447Open

Financial data

367 concepts · 6,139 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial335 concepts · 5,758 facts · Dec 2018 to Sep 2026

  • Cash cash equivalents restricted cash and restricted cash equivalents40 · Dec 2018 to Sep 2026
  • Stockholders equity (US GAAP)40 · Dec 2018 to Sep 2026
  • Accretion amortization of discounts and premiums investments39 · Dec 2018 to Sep 2026
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value39 · Dec 2018 to Sep 2026
  • Allocated share based compensation expense39 · Dec 2018 to Sep 2026
  • Antidilutive securities excluded from computation of earnings per share amount39 · Dec 2018 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect39 · Dec 2018 to Sep 2026
  • Comprehensive income net of tax39 · Dec 2018 to Sep 2026
  • Increase decrease in accounts payable39 · Dec 2018 to Sep 2026
  • Increase decrease in accrued liabilities39 · Dec 2018 to Sep 2026
  • Increase decrease in prepaid deferred expense and other assets39 · Dec 2018 to Sep 2026
  • Net cash provided by used in financing activities39 · Dec 2018 to Sep 2026
  • Net cash provided by used in investing activities39 · Dec 2018 to Sep 2026
  • Net cash provided by used in operating activities39 · Dec 2018 to Sep 2026
  • Net income loss39 · Dec 2018 to Sep 2026
  • Operating income loss39 · Dec 2018 to Sep 2026
  • Operating lease liabilities39 · Dec 2018 to Sep 2026
  • Other comprehensive income unrealized holding gain loss on securities arising during period net of tax39 · Dec 2018 to Sep 2026
  • Payments to acquire available for sale securities debt39 · Dec 2018 to Sep 2026
  • Payments to acquire property plant and equipment39 · Dec 2018 to Sep 2026
  • Proceeds from stock options exercised39 · Dec 2018 to Sep 2026
  • Research and development expense39 · Dec 2018 to Sep 2026
  • Share based compensation39 · Dec 2018 to Sep 2026
  • Share based compensation arrangement by share based payment award options outstanding intrinsic value37 · Dec 2018 to Sep 2026

Segment16 concepts · 233 facts · Dec 2022 to Sep 2026

  • Research and development expense55 · Dec 2022 to Sep 2026
  • Costs and expenses15 · Dec 2022 to Sep 2026
  • Income tax expense benefit15 · Dec 2022 to Sep 2026
  • Interest expense nonoperating15 · Dec 2022 to Sep 2026
  • Net income loss15 · Dec 2022 to Sep 2026
  • Operating income loss15 · Dec 2022 to Sep 2026
  • Other nonoperating income expense15 · Dec 2022 to Sep 2026
  • Reportable Segment15 · Dec 2022 to Sep 2026
  • Revenue15 · Dec 2022 to Sep 2026
  • Segment reporting other item amount15 · Dec 2022 to Sep 2026
  • Cost of goods and services sold (US GAAP)14 · Dec 2022 to Jun 2026
  • Selling general and administrative expense14 · Dec 2022 to Jun 2026
  • Investment income interest6 · Mar 2025 to Sep 2026
  • Interest income other5 · Dec 2023 to Mar 2026
  • Cost of goods and service excluding depreciation depletion and amortization2 · Sep 2025 to Sep 2026
  • Selling, General and Administrative Expense, Excluding Depreciation2 · Sep 2025 to Sep 2026

Product1 concept · 85 facts · Dec 2020 to Sep 2026

  • Revenue85 · Dec 2020 to Sep 2026

KPI14 concepts · 51 facts · Sep 2025 to Sep 2026

  • Cost of sales4 · Sep 2025 to Sep 2026
  • Income (loss) before income taxes4 · Sep 2025 to Sep 2026
  • Income (loss) from operations4 · Sep 2025 to Sep 2026
  • Interest income4 · Sep 2025 to Sep 2026
  • Net income (loss)4 · Sep 2025 to Sep 2026
  • Other income (expense), net4 · Sep 2025 to Sep 2026
  • Provision for income taxes4 · Sep 2025 to Sep 2026
  • Research and development4 · Sep 2025 to Sep 2026
  • Selling, general, and administrative4 · Sep 2025 to Sep 2026
  • Total operating expenses4 · Sep 2025 to Sep 2026
  • Total other income (expense)4 · Sep 2025 to Sep 2026
  • Total revenues4 · Sep 2025 to Sep 2026
  • Interest expense2 · Sep 2025 to Sep 2026
  • Other revenue1 · Sep 2025

Guidance1 concept · 12 facts · Jan 2025 to Nov 2026

  • Revenue Guidance12 · Jan 2025 to Nov 2026

Segments

318 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments1 member · 233 facts

  • Reportable233 · Dec 2022 to Sep 2026

Product or service7 members · 85 facts

  • ZORYVE Foam19 · Dec 2022 to Sep 2026
  • ZORYVE Cream0.1517 · Dec 2022 to Sep 2026
  • ZORYVE Cream0.317 · Dec 2022 to Sep 2026
  • Product10 · Dec 2020 to Dec 2023
  • ZORYVE Cream0.0510 · Dec 2023 to Sep 2026
  • Other Revenue7 · Dec 2021 to Dec 2023
  • ZORYVE Cream5 · Mar 2023 to Mar 2025

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary10 claims from 1 report · Sep 2026
  • Risk-factor changes84 claims from 4 reports · Dec 2021 to Dec 2024
  • Risk factors345 risks from 5 annual reports · 2020 to 2024

Earnings calls

2 calls · Aug 2026 to Nov 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q3Nov 4, 2026
  • FY2026 Q2Aug 5, 2026

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Arcutis Biotherapeutics, Inc. (ARQT) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 11, 2026) and refreshed every few hours.